Join leading hepatologists Dr. Jim Boyer and Dr. Palak Trivedi as they delve into the latest advancements and challenges in diagnosing and managing primary biliary cholangitis (PBC). This comprehensive HCPLive Special Report is divided into five segments, each addressing critical aspects of PBC care.
Segment 1: Explore advancements in PBC diagnostics, including the significance of anti-mitochondrial antibodies (AMA) and the use of transient elastography (FibroScan) for staging.
Segment 2: Discover recent therapeutic developments, focusing on new treatments like elafibranor and seladelpar, offering hope for patients who don't respond to traditional therapies.
Segment 3: Address unmet needs from clinical and patient perspectives, emphasizing the importance of achieving lower alkaline phosphatase levels and improving quality of life by managing symptoms like pruritus and fatigue.
Segment 4: Learn about promising emerging therapies, including next-generation PPAR agonists and IBAT inhibitors, which show potential in reducing cholestasis and improving cognitive impairment.
Segment 5: Get strategies for better supporting PBC patients through early diagnosis and patient empowerment initiatives, such as optimized consultations and comprehensive care plans.
This report offers invaluable insights for clinicians dedicated to improving outcomes for PBC patients. Don't miss these expert discussions!
Subject Matter Experts:
James Boyer, MD, Ensign Professor of Medicine at Yale School of Medicine and the Founder and Emeritus Director of the Yale Liver Center.
Palak Trivedi, MD, PhD, Associate Professor and Honorary Consultant Hepatologist and Clinical Research Director for Industry Engagement at the University of Birmingham. Also serves as an investigator on the open-label ASSURE trial of seladelpar in patients with PBC.